Benefits
Sleep onset latency — modest effect in adults
In primary sleep disorders, melatonin reduces sleep onset latency by approximately 7 minutes and increases total sleep time by approximately 8 minutes vs placebo — effect sizes that are statistically significant but clinically modest. Dose-response analyses indicate effect peaks at 4 mg/day administered 3 hours before bedtime. Honest framing: effect is much smaller than benzodiazepines or Z-drugs, but with a far better long-term safety profile.
Children and adolescents — stronger evidence than adults
Pooled analysis found melatonin significantly improves sleep onset latency and total sleep time in children and adolescents with chronic insomnia, but not in adults with non-comorbid insomnia. Particularly effective in pediatric autism spectrum disorder (ASD), ADHD, and neurodevelopmental disorders where intrinsic melatonin signaling may be disrupted. One of the few sleep aids with evidence-based pediatric use.
Jet lag — strongest single indication
Cochrane review supports melatonin for jet lag, particularly when crossing 5+ time zones eastward (the direction with the worst circadian disruption). Standard protocol: 0.5-3 mg at destination bedtime starting day of arrival, continuing for 2-5 days. Reduces jet lag severity (fatigue, daytime drowsiness, sleep disturbance) and accelerates circadian re-entrainment. One of the few sleep applications where melatonin's evidence is robust and consensus-supported.
Shift work sleep disorder
Modest evidence for daytime sleep improvement in night-shift workers when taken before daytime sleep periods. A Cochrane review found daytime sleep about 24 minutes longer with melatonin and no measurable change in how fast workers fell asleep, and graded that evidence low quality; sleep quality itself did not clearly improve. Doesn't fully resolve circadian misalignment — best used as adjunct to bright-light therapy and proper sleep hygiene rather than a standalone solution. AAFP guidelines include melatonin as a reasonable option for shift work sleep disorder.
Eye health and AMD — observational signal only
A large retrospective cohort of adults aged 50+ found melatonin use associated with 58% lower age-related macular degeneration (AMD) development risk and 56% lower nonexudative-to-exudative progression risk. Critical caveat: this is observational data only, not a controlled trial. Hypothesis-generating, not causally established: people who take melatonin regularly differ from those who do not in ways a medical records database cannot capture, and no controlled trial has tested melatonin for AMD. This is not a reason to take melatonin for an eye disease. Mechanism plausibility: melatonin is produced locally in retina, declines with age, and has antioxidant and anti-VEGF activity.
Preoperative anxiety reduction
Pooled analyses show melatonin (3-5 mg, 60-90 min preoperatively) reduces preoperative anxiety compared with placebo by about 13 points on a 100 point scale, which Cochrane graded high quality evidence. Two small studies found no clear difference from midazolam, but Cochrane graded that comparison low quality, so equivalence with midazolam is not established. This is a premedication given by hospital teams in the hour before surgery rather than something to take on your own, and anyone facing an operation should tell the anesthesia team what they take. Effects on postoperative pain and opioid requirement have also been reported but with less consistent data.
Cancer-related fatigue (adjunctive oncology)
Multiple trials in chemotherapy and radiotherapy patients report small reductions in cancer-related fatigue at around 20 mg per day, far above sleep doses, and the results are not consistent. A pooled analysis of nine randomized trials found only a small overall effect that reached significance mainly in trials running 13 weeks or longer, and a double-blind crossover trial of 20 mg in advanced cancer found no benefit on fatigue at all. Mechanism involves antioxidant, anti-inflammatory, and circadian effects. Independent replication exists but remains limited. Best framed as supportive care studied under oncology supervision, not a cancer treatment and not something to start on your own during chemotherapy.
Migraine prevention — preliminary
One randomized trial in 196 adults compared melatonin 3 mg, amitriptyline 25 mg and placebo over three months. Melatonin cut migraine days by 2.7 a month against 1.1 on placebo and was better tolerated than amitriptyline, and the difference between melatonin and amitriptyline was not statistically significant, which is not the same as showing the two are equal. Evidence base is smaller than for established preventives like topiramate or CGRP antagonists. It is not first line in current migraine prevention guidelines and is not a substitute for a preventive a doctor has prescribed.
Most products contain the wrong dose
An independent analysis of 31 melatonin products bought in Canada found more than 71% deviated by 10% or more from label claim, with actual content ranging from -83% to +478% of the labeled amount, and about a quarter also contained serotonin. In the US market, a 2023 JAMA analysis of 25 melatonin gummies found 22 were inaccurately labeled, with melatonin content from 74% to 347% of the label. Many retail tablets contain 5-10 mg — far above physiological doses (0.3-1 mg). Practical recommendation: choose USP-verified products and start at 0.5-1 mg. The pooled dose-response curve peaks at about 4 mg, so the 5 to 10 mg tablets that fill most shelves add grogginess rather than sleep. Regulation also differs by country: melatonin is sold as a supplement in the United States and Canada, but in the United Kingdom it is prescription only, in Australia most forms need a prescription apart from a 2 mg modified-release tablet a pharmacist may supply to adults aged 55 and over, and European countries are split between treating it as a medicine and allowing low-dose supplements. Where it is regulated as a medicine it is made to drug manufacturing standards, which is one reason label accuracy is a bigger problem in the US supplement market.
Mechanism of action
Circadian rhythm regulation
Melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus — the master circadian clock — signaling biological darkness and synchronizing the body's sleep-wake cycle with the day-night cycle. Endogenous secretion is suppressed by light (especially blue wavelengths) and rises in darkness.
Sleep onset facilitation via SCN inhibition
By activating melatonin receptors in the SCN, melatonin inhibits wake-promoting signals from the ventrolateral preoptic nucleus, reducing alertness and facilitating sleep initiation. Unlike benzodiazepines and Z-drugs, melatonin doesn't directly cause sedation — it shifts the circadian phase and removes wake drive, allowing natural sleep onset.
Direct and indirect antioxidant activity
Melatonin directly neutralizes reactive oxygen and nitrogen species and upregulates endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase). It crosses cell membranes and the blood-brain barrier easily, providing antioxidant protection in tissues where other antioxidants don't reach efficiently. The antioxidant role may underlie some non-sleep applications.
Anti-inflammatory effects
Melatonin inhibits pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and modulates NF-κB signaling — a central inflammatory pathway. These effects extend to the brain, immune system, and peripheral tissues, contributing to melatonin's broader proposed applications beyond sleep.
GABA and serotonin modulation
Melatonin enhances GABA-A receptor activity, contributing to its calming and anxiolytic effects (relevant for preoperative anxiety applications). It may also modulate serotonin levels indirectly — melatonin is synthesized from serotonin via N-acetyltransferase and 5-HIOMT — contributing to mood regulation and sleep architecture.
Neuroprotective and retinal effects
By reducing oxidative stress and stabilizing neuronal membranes, melatonin protects brain cells in models of neurodegeneration. The retina specifically produces its own melatonin, with levels declining with age — this local production decline may be mechanistically relevant to age-related macular degeneration risk.
Autonomic nervous system regulation
Melatonin reduces sympathetic nervous system activity and increases parasympathetic tone, contributing to lower heart rate, blood pressure, and the overall physiological 'wind-down' that precedes sleep. May explain the modest antihypertensive effects reported in some trials.
Immune system modulation
Melatonin influences immune cell function — enhancing T-cell activity, supporting natural killer (NK) cell function, and balancing pro- and anti-inflammatory cytokine production. Mechanism behind some of melatonin's proposed adjunctive oncology and immune-support applications, though clinical evidence in healthy adults is limited.
Clinical trials
Evidence review and dose-response pooled analysis of melatonin supplementation for sleep outcomes. Modern methodology evaluating both dose-response and timing-response relationships. Published in Journal of Pineal Research by Cruz-Sanabria and colleagues, 2024.
1,689 observations across 26 clinical trials published 1989-2020. Various adult populations.
Sleep onset latency reduction and total sleep time increase both peak at approximately 4 mg/day. Timing is critical: 3 hours before bedtime produces the maximum effect, vs the more common 30-60 minute pre-bedtime use. Establishes both optimal dose and timing for harder sleep cases beyond the typical sleep hygiene context.
Pooled analysis specifically stratifying melatonin trials by age group (children/adolescents vs adults) and by insomnia type (non-comorbid vs comorbid). Published in Sleep Medicine Reviews by Choi and colleagues, 2022. Addresses long-standing ambiguity about melatonin's age-specific efficacy.
1,912 participants across 24 clinical trials (20 non-comorbid insomnia + 4 comorbid insomnia).
Significant improvement in sleep onset latency and total sleep time in children and adolescents. Not significantly effective in adults with non-comorbid insomnia. This finding has important implications: many marketing claims about melatonin for adult sleep don't have meta-analytical support, but the pediatric evidence is genuinely strong.
Pooled analysis of randomized controlled trials of melatonin supplementation for primary sleep disorders. Published in PLOS One by Ferracioli-Oda and colleagues, 2013. Established the broadly-cited 'modest but real' effect size for melatonin in general adult populations.
1,683 subjects with primary sleep disorders across 19 clinical trials.
Sleep latency reduced by approximately 7 minutes (WMD -7.06, 95% CI -9.75 to -4.37, p<0.001). Total sleep time increased by approximately 8 minutes (WMD 8.25, p=0.013). Sleep quality improved modestly. Effect sizes are statistically significant but clinically modest — much smaller than prescription sleep medications, with much better safety profile.
Retrospective cohort analysis using the TriNetX electronic medical records database to evaluate associations between melatonin use and AMD outcomes. Published in JAMA Ophthalmology. Observational design with appropriate propensity-score matching.
121,523 adults aged 50+. Sub-analysis of 66,253 with existing nonexudative AMD.
Melatonin use associated with 58% lower risk of a new AMD diagnosis (risk ratio 0.42) and 56% lower risk of progression from nonexudative to exudative AMD (risk ratio 0.44). Critical caveat: this is observational data, not a controlled trial — strong unmeasured confounding is plausible. Hypothesis-generating for future controlled trials, not yet establishing causation.
Rossignol and Frye 2011, a systematic review of 35 studies with a meta-analysis of five randomized double-blind placebo-controlled trials of melatonin in children with autism spectrum disorder (ASD) — the population with the strongest pediatric sleep evidence. Includes both immediate-release and extended-release formulations across the pediatric dose range.
Children and adolescents with autism spectrum disorder and sleep disturbance across multiple trials.
Melatonin at 1-10 mg reduced sleep onset latency by about 39 minutes and increased total sleep by about 44 minutes against placebo in children with ASD — much larger effect sizes than in adult populations. Effects emerge within weeks and are sustained with continued use. Strongest pediatric evidence base in melatonin research; foundational for current neurodevelopmental sleep treatment protocols.